The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

The bladder cancer market is projected to reach $16 billion across 8 major markets (8MM) by 2033, driven by new therapies and ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...